Lantern Pharma Company Leadership
| LTRN Stock | USD 3.07 0.06 1.92% |
Lantern Pharma's insiders are aggressively selling. The analysis of the overall insider sentiment regarding Lantern Pharma suggests that virtually all insiders are panicking. Lantern Pharma employs about 21 people. The company is managed by 7 executives with a total tenure of roughly 49 years, averaging almost 7.0 years of service per executive, having 3.0 employees per reported executive.
Lantern Pharma's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2024-05-23 | Aaron G.L. Fletcher | Disposed 10000 @ 6.25 | View | ||
| 2024-02-28 | Aaron G.L. Fletcher | Disposed 74297 @ 4.85 | View | ||
| 2024-01-17 | Aaron G.L. Fletcher | Disposed 58889 @ 4.2 | View | ||
| 2023-11-29 | Leslie W Kreis | Disposed 145348 @ 3.44 | View |
Monitoring Lantern Pharma's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Lantern |
Lantern Pharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.2807) % which means that it has lost $0.2807 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4482) %, meaning that it created substantial loss on money invested by shareholders. Lantern Pharma's management efficiency ratios could be used to measure how well Lantern Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of November 2024, Return On Tangible Assets is likely to drop to -0.38. In addition to that, Return On Capital Employed is likely to grow to -0.41. At this time, Lantern Pharma's Non Current Assets Total are very stable compared to the past year. As of the 27th of November 2024, Non Currrent Assets Other is likely to grow to about 47.8 K, while Total Assets are likely to drop about 36.4 M.As of the 27th of November 2024, Common Stock Shares Outstanding is likely to drop to about 9.4 M. In addition to that, Net Loss is likely to grow to about (12.2 M)
Lantern Pharma Workforce Comparison
Lantern Pharma is rated fifth overall in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 410. Lantern Pharma holds roughly 21.0 in number of employees claiming about 5% of equities under Health Care industry.
Lantern Pharma Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lantern Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lantern Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Lantern Pharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-09-01 | 8.0 | 8 | 1 | 180,832 | 3,832 |
| 2024-03-01 | 0.2308 | 6 | 26 | 158,042 | 439,380 |
| 2022-12-01 | 0.1 | 1 | 10 | 3,200 | 700,000 |
| 2022-09-01 | 1.8333 | 11 | 6 | 282,352 | 15,440 |
| 2022-03-01 | 1.0 | 2 | 2 | 95,779 | 70,694 |
| 2020-06-01 | 2.1818 | 24 | 11 | 3,682,998 | 696,318 |
Lantern Pharma Notable Stakeholders
A Lantern Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Lantern Pharma often face trade-offs trying to please all of them. Lantern Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Lantern Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Panna Sharma | CEO President | Profile | |
| David Margrave | CFO Secretary | Profile | |
| DVM MS | CoFounder Advisor | Profile | |
| Nicole Leber | Finance Associate | Profile | |
| MS BS | Head Operations | Profile | |
| Kishor Bhatia | Chief Consultant | Profile | |
| Marc MD | Chief Therapeutics | Profile |
About Lantern Pharma Management Performance
The success or failure of an entity such as Lantern Pharma often depends on how effective the management is. Lantern Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Lantern management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Lantern management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.37) | (0.38) | |
| Return On Capital Employed | (0.44) | (0.41) | |
| Return On Assets | (0.37) | (0.38) | |
| Return On Equity | (0.39) | (0.37) |
Lantern Pharma Workforce Analysis
Traditionally, organizations such as Lantern Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Lantern Pharma within its industry.Lantern Pharma Manpower Efficiency
Return on Lantern Pharma Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 760.1K | |
| Net Loss Per Executive | 2.3M | |
| Working Capital Per Employee | 1.9M | |
| Working Capital Per Executive | 5.8M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lantern Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.78) | Return On Assets (0.28) | Return On Equity (0.45) |
The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.